Adriano Piris
Research Subjects
Adriano Piris has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer Ann Wargo
The University of Texas MD Anderson Cancer Center
5 shared publications - Keith T. Flaherty
Massachusetts General Hospital, Boston, MA
5 shared publications - Cory M. Johannessen
Broad Institute of MIT and Harvard, Cambridge, USA
3 shared publications - David E. Fisher
Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA
3 shared publications - David J. Konieczkowski
Department of Radiation Oncology, James Cancer Center, The Ohio State University, Columbus, OH
3 shared publications - Dennie T. Frederick
Broad Institute
3 shared publications
Latest Publications
- 16 November 2025
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 53 (1) , 28
Dr. Martin C. Mihm Jr., My Mentor, My Friend, My Family
- 16 November 2025
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 53 (1) , 28
Dr. Martin C. Mihm Jr., My Mentor, My Friend, My Family
- 2 February 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (8) , 1901-1904.e2
Desmoplasia Is Associated with Decreased Cytotoxic and Helper T Cells and Increased T-Cell Exhaustion in Cutaneous Squamous Cell Carcinoma
- 2 February 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (8) , 1901-1904.e2
Desmoplasia Is Associated with Decreased Cytotoxic and Helper T Cells and Increased T-Cell Exhaustion in Cutaneous Squamous Cell Carcinoma
- 28 July 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (2) , 407-409
A Proposed Grading System for Desmoplasia in Cutaneous Squamous Cell Carcinoma Predicts Death from Disease
- 28 July 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (2) , 407-409
A Proposed Grading System for Desmoplasia in Cutaneous Squamous Cell Carcinoma Predicts Death from Disease
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S2 from A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
PDF file 89K, This file contains a table listing the top 75 genes correlated with RAF-inhibitor sensitivity in BRAFV600E-mutant cell lines as well as a table describing the IHC results summarized in Main Figure 2b and 2c
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S2 from A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
PDF file 89K, This file contains a table listing the top 75 genes correlated with RAF-inhibitor sensitivity in BRAFV600E-mutant cell lines as well as a table describing the IHC results summarized in Main Figure 2b and 2c
- 1 November 2013
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 12 (11_Supplem) , C137
Abstract C137: Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients.
The clinical development of selective RAF and MEK inhibitors has transformed the treatment of the ∼50% of melanoma patients whose tumors harbor BRAF mutations. However, a substantial percentage of these patients fail to respond to therapy, and most responses are partial and short-lived. Although multiple mechanisms of resistance have been identified in BRAF-mutant melanoma, no clinically useful biomarkers have been established to predict which patients are most likely to demonstrate sensitivity or resistance to RAF or MEK inhibitors. We found that suppression of TORC1 activity in response to RAF or MEK inhibitors, as measured by decreased phosphorylation of ribosomal protein-S6 (P-S6), was a functional biomarker that effectively predicted sensitivity in BRAF-mutant melanoma cell lines in vitro and in mouse tumor xenografts. In sensitive melanomas, TORC1 and P-S6 were suppressed in response to RAF or MEK inhibitors, but in resistant melanomas, TORC1 activity was maintained, in some cases despite robust suppression of MAPK signaling by these inhibitors. In mouse models, suppression of TORC1 after MAPK inhibition was necessary for induction of apoptosis and tumor response in vivo. Notably, in paired biopsies obtained from patients with BRAF-mutant melanoma before treatment and after initiation of RAF inhibitor therapy, P-S6 suppression was associated with significantly improved progression-free survival [HR 0.19, 95% CI 0.01-0.84, p=0.03]. Finally, we found that changes in P-S6 in patients’ tumor cells could be readily monitored in real-time by multiplexed, quantitative immunofluorescence microscopy of serial fine-needle aspiration biopsies obtained from patients before and during the first 2 weeks of RAF inhibitor therapy. This approach provides a minimally-invasive means of rapidly monitoring the efficacy of treatment, before changes in tumor volume are apparent by traditional radiographic imaging. Together, these results establish suppression of P-S6 after initiation of RAF inhibitor therapy as a robust potential functional biomarker to guide the treatment of patients with BRAF-mutant melanoma, and present a powerful methodology for monitoring changes in potentially any signaling pathway in response to targeted therapies in patients. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):C137. Citation Format: Ryan B. Corcoran, S. Michael Rothenberg, Aaron N. Hata, Anthony C. Faber, Adriano Piris, Rosalynn M. Nazarian, Ronald D. Brown, Jason T. Godfrey, Daniel Winokur, John Walsh, Mari Mino-Kenudson, Shyamala Maheswaran, Jeffrey Settleman, Jennifer A. Wargo, Keith T. Flaherty, Daniel A. Haber, Jeffrey A. Engelman. Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr C137.
- 1 November 2013
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 12 (11_Supplem) , C137
Abstract C137: Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients.
The clinical development of selective RAF and MEK inhibitors has transformed the treatment of the ∼50% of melanoma patients whose tumors harbor BRAF mutations. However, a substantial percentage of these patients fail to respond to therapy, and most responses are partial and short-lived. Although multiple mechanisms of resistance have been identified in BRAF-mutant melanoma, no clinically useful biomarkers have been established to predict which patients are most likely to demonstrate sensitivity or resistance to RAF or MEK inhibitors. We found that suppression of TORC1 activity in response to RAF or MEK inhibitors, as measured by decreased phosphorylation of ribosomal protein-S6 (P-S6), was a functional biomarker that effectively predicted sensitivity in BRAF-mutant melanoma cell lines in vitro and in mouse tumor xenografts. In sensitive melanomas, TORC1 and P-S6 were suppressed in response to RAF or MEK inhibitors, but in resistant melanomas, TORC1 activity was maintained, in some cases despite robust suppression of MAPK signaling by these inhibitors. In mouse models, suppression of TORC1 after MAPK inhibition was necessary for induction of apoptosis and tumor response in vivo. Notably, in paired biopsies obtained from patients with BRAF-mutant melanoma before treatment and after initiation of RAF inhibitor therapy, P-S6 suppression was associated with significantly improved progression-free survival [HR 0.19, 95% CI 0.01-0.84, p=0.03]. Finally, we found that changes in P-S6 in patients’ tumor cells could be readily monitored in real-time by multiplexed, quantitative immunofluorescence microscopy of serial fine-needle aspiration biopsies obtained from patients before and during the first 2 weeks of RAF inhibitor therapy. This approach provides a minimally-invasive means of rapidly monitoring the efficacy of treatment, before changes in tumor volume are apparent by traditional radiographic imaging. Together, these results establish suppression of P-S6 after initiation of RAF inhibitor therapy as a robust potential functional biomarker to guide the treatment of patients with BRAF-mutant melanoma, and present a powerful methodology for monitoring changes in potentially any signaling pathway in response to targeted therapies in patients. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):C137. Citation Format: Ryan B. Corcoran, S. Michael Rothenberg, Aaron N. Hata, Anthony C. Faber, Adriano Piris, Rosalynn M. Nazarian, Ronald D. Brown, Jason T. Godfrey, Daniel Winokur, John Walsh, Mari Mino-Kenudson, Shyamala Maheswaran, Jeffrey Settleman, Jennifer A. Wargo, Keith T. Flaherty, Daniel A. Haber, Jeffrey A. Engelman. Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr C137.
- 15 May 2012
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (10_Supplem) , PR8
Abstract PR8: Insensitivity to RAF inhibition by vemurafenib in BRAF mutant colorectal cancer by EGFR-mediated reactivation of MAPK signaling
BRAF mutations occur in 10–15% of colorectal cancers (CRCs) and confer adverse outcome in the metastatic setting. While RAF inhibitors such as vemurafenib (PLX4032) have proven effective in BRAF mutant melanoma (∼60–80% response rates), they are surprisingly ineffective in BRAF mutant CRCs (∼5% response rate), and the reason for this disparity remains unclear. Compared to BRAF mutant melanoma cells, BRAF mutant CRC cells were less sensitive to vemurafenib, and P-ERK suppression was not sustained in response to treatment. Although transient inhibition of phospho-ERK by vemurafenib was observed in CRC, rapid ERK re-activation occurred through EGFR-mediated activation of RAS and CRAF. BRAF mutant CRC cell lines and patient tumor specimens expressed significantly higher levels of phospho-EGFR than BRAF mutant melanoma cell lines and primary tumor specimens, suggesting that CRCs are specifically poised for EGFR-mediated resistance. Combined RAF and EGFR inhibition blocked reactivation of MAPK signaling in BRAF mutant CRC cells and markedly improved efficacy in vitro. In vivo, combined RAF and EGFR inhibition led to sustained suppression of MAPK signaling and to robust tumor regressions in BRAF mutant colorectal xenografts. These findings support evaluation of combined RAF and EGFR inhibition in clinical trials in patients with BRAF mutant CRC. This proffered talk is also presented as Poster B11.
- 15 May 2012
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (10_Supplem) , PR8
Abstract PR8: Insensitivity to RAF inhibition by vemurafenib in BRAF mutant colorectal cancer by EGFR-mediated reactivation of MAPK signaling
BRAF mutations occur in 10–15% of colorectal cancers (CRCs) and confer adverse outcome in the metastatic setting. While RAF inhibitors such as vemurafenib (PLX4032) have proven effective in BRAF mutant melanoma (∼60–80% response rates), they are surprisingly ineffective in BRAF mutant CRCs (∼5% response rate), and the reason for this disparity remains unclear. Compared to BRAF mutant melanoma cells, BRAF mutant CRC cells were less sensitive to vemurafenib, and P-ERK suppression was not sustained in response to treatment. Although transient inhibition of phospho-ERK by vemurafenib was observed in CRC, rapid ERK re-activation occurred through EGFR-mediated activation of RAS and CRAF. BRAF mutant CRC cell lines and patient tumor specimens expressed significantly higher levels of phospho-EGFR than BRAF mutant melanoma cell lines and primary tumor specimens, suggesting that CRCs are specifically poised for EGFR-mediated resistance. Combined RAF and EGFR inhibition blocked reactivation of MAPK signaling in BRAF mutant CRC cells and markedly improved efficacy in vitro. In vivo, combined RAF and EGFR inhibition led to sustained suppression of MAPK signaling and to robust tumor regressions in BRAF mutant colorectal xenografts. These findings support evaluation of combined RAF and EGFR inhibition in clinical trials in patients with BRAF mutant CRC. This proffered talk is also presented as Poster B11.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15_suppl) , 9020
Phospho-ERK (pERK) and Ki67 expression as compared to thickness and mitotic rate (MR) as prognostic factors in patients with stage I/II melanomas
9020 Background: Tumor thickness and MR in the vertical growth phase (VGP) are key prognostic factors for melanoma patients. We hypothesized that the expression of two biomarkers associated with proliferation, Ki67, a measure of cell division, and pERK, a consequence of melanoma cells signaling through the MAP kinase pathway, would be associated with poor prognosis and more accurately predict those who would have a metastasis within ten years (MET). Methods: We evaluated Ki67 and pERK expression by immunohistochemistry in a nested cohort study of 50 patients with stage I/II VGP melanomas seen at Penn's Pigmented Lesion Clinic (1972–91). Ki67 expression was determined by the % of melanoma cells positive in VGP hot spots. Nuclear pERK expression by melanoma cells in the tumor's invasive edge (pERK/IE) was quantified using a modified H-score. Cut-points for both were established by maximizing the difference between survival distributions. Fisher's exact test (0.05, one-sided) had 75% power to detect an odds ratio (OR) of 4.3 with 19 and 42 patients with and without MET. Results: The odds of MET were 10.6-fold and 4.3-fold higher in patients having high Ki67 (p=0.013) and high pERK/IE (p<0.01) expression, respectively, compared to those with low expression. Thickness (OR=1.7, p=0.004) and MR (OR=1.3, p=0.002) were also each associated with MET. In the multivariate model the adjusted odds ratios for Ki67 and pERK/IE remained strong [4.0 (p=0.061) and 5.9 (p=0.030)], but thickness and MR were no longer significant. Conclusions: New biomarkers strongly associated with clinical outcome are needed. Both Ki67 and pERK/IE expression were strongly associated with prognosis, were notably more informative than thickness and MR in predicting MET, and are therefore candidates for validation in larger datasets. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15_suppl) , 9020
Phospho-ERK (pERK) and Ki67 expression as compared to thickness and mitotic rate (MR) as prognostic factors in patients with stage I/II melanomas
9020 Background: Tumor thickness and MR in the vertical growth phase (VGP) are key prognostic factors for melanoma patients. We hypothesized that the expression of two biomarkers associated with proliferation, Ki67, a measure of cell division, and pERK, a consequence of melanoma cells signaling through the MAP kinase pathway, would be associated with poor prognosis and more accurately predict those who would have a metastasis within ten years (MET). Methods: We evaluated Ki67 and pERK expression by immunohistochemistry in a nested cohort study of 50 patients with stage I/II VGP melanomas seen at Penn's Pigmented Lesion Clinic (1972–91). Ki67 expression was determined by the % of melanoma cells positive in VGP hot spots. Nuclear pERK expression by melanoma cells in the tumor's invasive edge (pERK/IE) was quantified using a modified H-score. Cut-points for both were established by maximizing the difference between survival distributions. Fisher's exact test (0.05, one-sided) had 75% power to detect an odds ratio (OR) of 4.3 with 19 and 42 patients with and without MET. Results: The odds of MET were 10.6-fold and 4.3-fold higher in patients having high Ki67 (p=0.013) and high pERK/IE (p<0.01) expression, respectively, compared to those with low expression. Thickness (OR=1.7, p=0.004) and MR (OR=1.3, p=0.002) were also each associated with MET. In the multivariate model the adjusted odds ratios for Ki67 and pERK/IE remained strong [4.0 (p=0.061) and 5.9 (p=0.030)], but thickness and MR were no longer significant. Conclusions: New biomarkers strongly associated with clinical outcome are needed. Both Ki67 and pERK/IE expression were strongly associated with prognosis, were notably more informative than thickness and MR in predicting MET, and are therefore candidates for validation in larger datasets. No significant financial relationships to disclose.